ArticleScientific reports2026
Causal relevance of the JAK/STAT pathway for cardioprotection via cold acclimation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cardioprotective effect of cold acclimation (5 weeks; 9 °C; CA) and the same effect persisting 2 weeks after recovery from CA (CAR) are induced by different mechanisms. We showed that salvage β2-adrenoceptor/Gi/Akt pathway is only involved in the mechanism of cardioprotection after CAR. Since the mechanism of CA-elicited cardioprotection is not known, we examined the role of JAK2/STAT3 pathway. Male Wistar rats exposed to CA and controls (24 °C) were treated with the JAK2 inhibitor AG490 affecting downstream STAT3 signaling in the heart (5 mg/kg/day) for three days prior to the end of experiment. AG490 administration abolished CA-elicited reduction of infarct-size and significant improvement of MPT pore opening. IL-6, as the main STAT3 upstream effector, was upregulated by CA, and AG490 reversed its level. CA had no effect on IL-1β and TNF-α, but was upregulated by AG490 in controls, and downregulated in CA-AG490 group. CA also reduced pro-apoptotic p38-MAPK, which was abolished by AG490 administration. Spatial expression analyses revealed CA-elicited translocation of total-STAT3 from mitochondria to sarcolemma compartment which was eliminated by JAK2/STAT3 inhibition. However, CA-induced loss of pSTAT3Y705 from sarcolemma compartment, and loss of pSTAT3S727 from nucleus. These results identify non-genomic, mitochondria-associated STAT3 activity as a confirmed mechanism of CA-elicited cardioprotection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.